查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲分子肿瘤诊断市场：按癌症类型、最终用户和国家进行分析和预测（2024-2033）
市场调查报告书
商品编码
1752091

欧洲分子肿瘤诊断市场：按癌症类型、最终用户和国家进行分析和预测（2024-2033）

Europe Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 89 Pages | 商品交期: 1-5个工作天内

价格

欧洲分子肿瘤诊断市场规模预计将从 2024 年的 6.06 亿美元成长到 2033 年的 15.234 亿美元，复合年增长率为 10.78%。

次世代定序(NGS)、数位PCR和液态切片是推动欧洲分子肿瘤诊断市场扩张的部分技术进步，部分原因是该地区癌症成长要素的上升。这些进步有助于改善患者预后、提供更精准的治疗方案并实现更早的检测。

主要市场统计数据
预测期 2024-2033
2024年评估 6.06亿美元
2033年预测 15.234亿美元
复合年增长率 10.78%

然而，分子肿瘤诊断市场渗透面临许多区域性障碍。由于医疗预算有限，分子诊断测试的高成本仍然是一项重大挑战，尤其是在中欧和东欧国家。此外，缺乏能够操作先进诊断设备和解读复杂基因组数据的专业人员也阻碍了其在临床环境中的广泛应用。

儘管面临诸多挑战，欧洲市场仍在稳定成长。生物技术、製药、诊断设备製造商和学术研究机构之间的合作，正透过加强分子诊断工具与癌症治疗的整合来加速创新。为了充分发挥分子诊断在欧洲医疗保健体系中的潜力，必须努力降低检测成本，规范支付系统，并提高医生的基因组学素养。

市场区隔:

细分一：按癌症类型

  • 固体癌
  • 骨髓恶性肿瘤

细分 2：按最终用户

  • 医院和诊断中心
  • 参考实验室
  • 製药和生物技术公司
  • 学术和研究机构

细分3：按地区

  • 欧洲：英国、德国、法国、义大利、西班牙等。

本报告研究了欧洲分子肿瘤诊断市场，并总结了主要趋势、市场影响因素分析、法律制度、技术和专利分析、市场规模趋势和预测、各个细分市场、地区/主要国家、竞争格局的详细分析以及主要企业的概况。

目录

执行摘要

范围和定义

第一章欧洲分子肿瘤诊断市场：产业展望

  • 全球癌症发生率和盛行率（按癌症类型划分）
    • 欧洲
  • 趋势：现况与未来影响评估
    • 加强企业间合作
    • 增加分子肿瘤诊断生态系统中的创新产品发布和监管核准
  • 监管状况
    • 欧洲法律要求和框架
  • COVID-19 对分子肿瘤诊断市场的影响
  • 基于液态生物检体的分子癌症诊断
  • 实验室测试（LDT）和体外诊断（IVD）
  • 伴随诊断在分子肿瘤诊断市场中的作用
  • 市场动态
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章 分子肿瘤诊断市场（按地区）

  • 区域摘要
  • 驱动因素和约束因素
  • 欧洲
    • 区域概况
    • 市场成长动力
    • 市场问题
    • 按癌症类型
    • 按最终用户
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的

第三章分子肿瘤诊断市场：竞争基准化分析与公司概况

  • 关键策略发展
    • 伙伴关係、合作和业务扩展
    • 新服务
    • M&A
    • 监管和法律活动
  • 企业市场占有率分析
  • 公司简介
    • Biocartis Group NV
    • bioMerieux
    • F. Hoffmann-La Roche Ltd.
    • QIAGEN NV

第四章调查方法

Product Code: BHP3005SS

This report can be delivered in 2 working days.

Introduction to Europe Molecular Oncology Diagnostics Market

The Europe molecular oncology diagnostics market was valued at $606.0 million in 2024, and the market is expected to grow with a CAGR of 10.78% and reach $1,523.4 million by 2033. Next-generation sequencing (NGS), digital PCR, and liquid biopsy are just a few of the technological advancements driving the European molecular oncology diagnostics market's expansion. The region's rising cancer incidence is another factor. Better patient outcomes, more accurate treatment choices, and earlier detection are made possible by these advancements.

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$606.0 Million
2033 Forecast$1,523.4 Million
CAGR10.78%

However, there are a number of regional obstacles to market penetration. The high expense of molecular diagnostic testing remains a hurdle, especially in nations with relatively limited healthcare budgets in Central and Eastern Europe. Furthermore, wider clinical usage is constrained by a lack of qualified personnel who can operate sophisticated diagnostic tools and decipher complicated genomic data.

The European market continues to grow in spite of these challenges. The integration of molecular tools into routine oncology care is being supported and innovation is being accelerated by cooperative efforts involving biotech companies, pharmaceutical companies, diagnostic producers, and academic research centres. Unlocking the full potential of molecular diagnostics in cancer management across various European healthcare systems would require efforts to standardise payment regulations, lower test prices, and increase clinician genomic literacy.

Market Introduction

The market for molecular oncology diagnostics in Europe is changing dramatically as more healthcare systems embrace precision medicine methods for treating cancer. Molecular diagnostics is becoming more and more important in detecting genetic changes connected to different types of cancer, driven by the demand for earlier detection, more precise diagnosis, and customised therapy planning. Advanced testing systems that support targeted therapies and enhance treatment outcomes are becoming more and more in demand in the region.

Adoption is accelerating in Western Europe, especially in nations like Germany, the UK, and France, because to established healthcare systems, benevolent legal environments, and rising genomic research expenditures. Central and Eastern Europe is progressively catching up, though, as initiatives are being made to standardise cancer treatment internationally and increase access to molecular diagnostics.

The market is also benefiting from the continuous integration of digital health, as oncology centres and labs use genetic data platforms to make decisions in real time. Demand in the market is also being driven by growing applications in risk stratification, treatment monitoring, and early diagnosis as well as rising awareness among physicians and patients. Europe is positioned to become a major centre for molecular oncology diagnostics, influencing the direction of customised cancer treatment in a variety of clinical settings as long as public and private health authorities keep funding innovation and capacity-building.

Market Segmentation:

Segmentation 1: by Cancer Type

  • Solid Tumors
  • Hematologic Malignancies

Segmentation 2: by End User

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Segmentation 3: by Region

  • Europe - U.K., Germany, France, Italy, Spain, and Rest-of-Europe

Europe Molecular Oncology Diagnostics Market Trends, Drivers & Challenges:

Market Trends

  • Expansion of Next-Generation Sequencing (NGS) Panels: Increasing use of multiplexed NGS assays for simultaneous detection of multiple oncogenic mutations, enabling broader genomic profiling.
  • Growth of Liquid Biopsy Adoption: Rising preference for minimally invasive circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) assays to monitor treatment response and detect early relapse.
  • Integration with Immuno-Oncology: Molecular diagnostics platforms increasingly incorporate biomarkers (e.g., PD-L1, TMB) to guide immune checkpoint inhibitor therapies.
  • Emergence of Companion Diagnostics: Co-development of targeted therapies and associated diagnostic tests is accelerating regulatory approvals and market uptake.

Market Drivers

  • Rising Cancer Incidence & Aging Population: Europe's growing elderly demographic and higher cancer prevalence boost demand for precise diagnostic tools.
  • Shift Toward Precision Medicine: Clinicians and payers favor personalized treatment plans, driving investment in molecular assays that predict therapy efficacy.
  • Favorable Reimbursement Policies: Several European healthcare systems and HTA agencies are approving broader coverage for advanced genomic tests, reducing out-of-pocket costs.
  • Technological Advancements & Cost Reductions: Continuous improvements in assay sensitivity, turnaround time, and economies of scale are making molecular tests more accessible.

Market Challenges

  • High Test Development & Implementation Costs: Building validated panels and obtaining regulatory clearances remain expensive, limiting adoption in smaller hospitals.
  • Fragmented Reimbursement Landscape: Inconsistent coverage policies across EU member states and varied HTA requirements create uncertainty for providers and manufacturers.
  • Standardization & Quality Control Issues: Lack of uniform guidelines for assay validation, interpretation, and reporting can hamper cross-laboratory comparability.
  • Data Privacy & Regulatory Complexity: Strict GDPR requirements and evolving IVDR regulations increase administrative burden and slow down clinical deployment.

Some of the prominent key players in this market are:

  • Biocartis Group NV
  • bioMerieux
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Molecular Oncology Diagnostics Market: Industry Outlook

  • 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type)
    • 1.1.1 Europe
  • 1.2 Trends: Current and Future Impact Assessment
    • 1.2.1 Increasing Partnerships among Players
    • 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem
  • 1.3 Regulatory Landscape
    • 1.3.1 Legal Requirements and Framework in Europe
  • 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
  • 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
  • 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD)
  • 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market
  • 1.8 Market Dynamics
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Incidence of Cancer Cases
      • 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics
      • 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques
      • 1.8.1.4 Growing Demand for Personalized Medicine
    • 1.8.2 Market Challenges
      • 1.8.2.1 Lack of Qualified Professionals
      • 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics
      • 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics
      • 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies

2 Molecular Oncology Diagnostics Market: by Region

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 By Cancer Type
    • 2.3.5 By End User
    • 2.3.6 Germany
      • 2.3.6.1 By Cancer Type
      • 2.3.6.2 By End User
    • 2.3.7 France
      • 2.3.7.1 By Cancer Type
      • 2.3.7.2 By End User
    • 2.3.8 U.K.
      • 2.3.8.1 By Cancer Type
      • 2.3.8.2 By End User
    • 2.3.9 Italy
      • 2.3.9.1 By Cancer Type
      • 2.3.9.2 By End User
    • 2.3.10 Spain
      • 2.3.10.1 By Cancer Type
      • 2.3.10.2 By End User
    • 2.3.11 Rest-of-Europe
      • 2.3.11.1 By Cancer Type
      • 2.3.11.2 By End User

3 Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles

  • 3.1 Key Strategic Development
    • 3.1.1 Partnerships, Alliances, and Business Expansions
    • 3.1.2 New Offerings
    • 3.1.3 Mergers and Acquisitions
    • 3.1.4 Regulatory and Legal Activities
  • 3.2 Company Share Analysis
  • 3.3 Company Profiles
    • 3.3.1 Biocartis Group NV
      • 3.3.1.1 Overview
      • 3.3.1.2 Top Products
      • 3.3.1.3 Top Competitors
      • 3.3.1.4 Target Customers/End User
      • 3.3.1.5 Key Personnel
      • 3.3.1.6 Analyst View
    • 3.3.2 bioMerieux
      • 3.3.2.1 Overview
      • 3.3.2.2 Top Products
      • 3.3.2.3 Top Competitors
      • 3.3.2.4 Target Customers/End User
      • 3.3.2.5 Key Personnel
      • 3.3.2.6 Analyst View
    • 3.3.3 F. Hoffmann-La Roche Ltd.
      • 3.3.3.1 Overview
      • 3.3.3.2 Top Products
      • 3.3.3.3 Top Competitors
      • 3.3.3.4 Target Customers/End User
      • 3.3.3.5 Key Personnel
      • 3.3.3.6 Analyst View
    • 3.3.4 QIAGEN N.V.
      • 3.3.4.1 Overview
      • 3.3.4.2 Top Products
      • 3.3.4.3 Top Competitors
      • 3.3.4.4 Target Customers/End User
      • 3.3.4.5 Key Personnel
      • 3.3.4.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1 Europe Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033
  • Figure 2 Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033
  • Figure 3 Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033
  • Figure 4 Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033
  • Figure 5 Role of Diagnostics in Healthcare
  • Figure 6 Cancer Prevalence and Incidence (by Cancer Type), in Million, Europe, 2022
  • Figure 7 Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 8 Technological Advances in Liquid Biopsy Analysis
  • Figure 9 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD
  • Figure 10 Prominent FDA-Approved Companion Diagnostics
  • Figure 11 Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 12 Global Distribution of Cases and Deaths (by Cancer Type), 2022
  • Figure 13 Global Incidence for Cancer Types, 2018-2022
  • Figure 14 Germany Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 15 France Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 16 U.K. Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 17 Italy Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 18 Spain Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 19 Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 20 Partnerships, Alliances, and Business Expansions, January 2021-July 2024
  • Figure 21 New Offerings, January 2021-July 2024
  • Figure 22 Mergers and Acquisitions, January 2021-July 2024
  • Figure 23 Regulatory and Legal Activities, January 2021-July 2024
  • Figure 24 Data Triangulation
  • Figure 25 Top-Down and Bottom-Up Approach
  • Figure 26 Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Key Trends, Impact Analysis
  • Table 3: Molecular Oncology Diagnostics Market, Partnerships and Collaborations
  • Table 4: Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals
  • Table 5: Molecular Oncology Diagnostics Market, New Offerings
  • Table 6: Biomarkers for Different Cancer Types
  • Table 7: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer
  • Table 8: Cost of Liquid Biopsy-Based NGS Kits
  • Table 9: Europe Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage
  • Table 10: Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033
  • Table 11: Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 12: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 13: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 14: Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 15: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 16: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 17: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 18: Germany Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 19: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 20: France Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 21: France Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 22: France Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 23: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 24: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 25: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 26: U.K. Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 27: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 28: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 29: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 30: Italy Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 31: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 32: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 33: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 34: Spain Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 35: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 36: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 37: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 38: Rest-of-Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 39: Europe Molecular Oncology Diagnostics Market, Company Share Analysis, 2023